These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 25043930)

  • 1. Rituximab-cyclophosphamide-dexamethasone is highly effective in patients with monoclonal Ig deposit-related glomerulopathy and indolent non-Hodgkin lymphomas.
    Perry M; Delarche A; Ribes D; Vergez F; Guilbeau-Frugier C; Laurent C; Huart A; Tavitian S; El Hachem H; Oberic L; Chauveau D; Michallet AS; Ysebaert L; Faguer S
    Am J Hematol; 2014 Oct; 89(10):969-73. PubMed ID: 25043930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
    Ribes D; Hachem HEL; Oberic L; Vergez F; Delas A; Belliere J; Protin C; Kamar N; Ferrandiz I; Tavitian S; Laurent C; Huart A; Chauveau D; Ysebaert L; Faguer S
    Am J Hematol; 2018 Mar; 93(3):356-362. PubMed ID: 29168251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
    Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
    Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE
    Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas.
    Fabbri A; Cencini E; Rigacci L; Bartalucci G; Puccini B; Dottori R; Gozzetti A; Bosi A; Bocchia M
    Leuk Lymphoma; 2014 Apr; 55(4):781-5. PubMed ID: 23876098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
    Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM
    Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
    Li X; Li H; Ye H; Li Q; He X; Zhang X; Chen Y; Han F; He Q; Wang H; Chen J
    Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
    Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
    Rigacci L; Puccini B; Cortelazzo S; Gaidano G; Piccin A; D'Arco A; Freilone R; Storti S; Orciuolo E; Zinzani PL; Zaja F; Bongarzoni V; Balzarotti M; Rota-Scalabrini D; Patti C; Gobbi M; Carpaneto A; Liberati AM; Bosi A; Iannitto E
    Ann Hematol; 2012 Jul; 91(7):1013-22. PubMed ID: 22349722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.
    Ferrario A; Pulsoni A; Olivero B; Rossi G; Vitolo U; Tedeschi A; Merli F; Rigacci L; Stelitano C; Goldaniga M; Mannina D; Musto P; Rossi F; Gamba E; Baldini L
    Cancer; 2012 Aug; 118(16):3954-61. PubMed ID: 22179904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
    Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
    Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
    Tam C; Seymour JF; Brown M; Campbell P; Scarlett J; Underhill C; Ritchie D; Bond R; Grigg AP
    Haematologica; 2005 May; 90(5):700-2. PubMed ID: 15921393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of patients with transformed lymphoma in the rituximab era.
    Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
    Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
    Tuscano JM; Dutia M; Chee K; Brunson A; Reed-Pease C; Abedi M; Welborn J; O'Donnell RT
    Br J Haematol; 2014 May; 165(3):375-81. PubMed ID: 24606326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab tolerability when given before or after CHOP.
    Hannawa IS; Bestul DJ
    J Oncol Pharm Pract; 2011 Dec; 17(4):381-6. PubMed ID: 21109616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
    Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membranoproliferative glomerulonephritis and light-chain nephropathy in association with chronic lymphocytic leukemia.
    Mutluay R; Aki SZ; Erten Y; Konca C; Yagci M; Barit G; Sindel S
    Clin Nephrol; 2008 Dec; 70(6):527-31. PubMed ID: 19049712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.